Dr. Ehsan Sadri, M.D.
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Medical school
- University of Michigan Medical School (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 303
Licensed in California since 2004, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: University of Michigan Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
CA license A87053 (first issued 2004; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 303
- Services billed
- 1,157
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 251 | 146 |
| Established patient complete exam of visual system | 175 | 127 |
| New patient complete exam of visual system | 104 | 104 |
| Imaging of optic nerve | 101 | 89 |
| Exam of visual field with extended testing | 88 | 83 |
| Imaging of retina | 65 | 60 |
| Removal of cataract with insertion of prosthetic lens | 59 | 36 |
| Measurement of corneal curvature and depth of eye | 55 | 52 |
| Ct scan of cornea | 50 | 47 |
| Exam of the internal drainage system of eye | 43 | 41 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Newport Beach, CA | 517 |
| Latanoprost Other prescribers in Newport Beach, CA | 481 |
| Ketorolac Tromethamine Other prescribers in Newport Beach, CA | 409 |
| Moxifloxacin (moxifloxacin hcl) Other prescribers in Newport Beach, CA | 391 |
| Timolol Maleate Other prescribers in Newport Beach, CA | 375 |
| Neomycin-Polymyxin-Dexameth (neomycin/polymyxin b/dexametha) Other prescribers in Newport Beach, CA | 154 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Newport Beach, CA | 138 |
| Brimonidine Tartrate Other prescribers in Newport Beach, CA | 74 |
| Restasis (cyclosporine) Other prescribers in Newport Beach, CA | 48 |
| Dorzolamide Hcl Other prescribers in Newport Beach, CA | 47 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 43 payments worth $3,808 in total to this clinician.
| Tarsus Pharmaceuticals, Inc. | $1,661 |
|---|---|
| Sun Pharmaceutical Industries Inc. | $448 |
| Alcon Research LLC | $318 |
| Bausch & Lomb Americas Inc. | $312 |
| Alcon Vision LLC | $266 |
| Johnson & Johnson Surgical Vision, Inc. | $250 |
| Dompe US, Inc. | $196 |
| Sight Sciences, Inc. | $168 |
| Food and Beverage | $2,308 |
|---|---|
| Consulting Fee | $1,500 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Tarsus Pharmaceuticals, Inc. May 14, 2025 | Consulting Fee | $1,500 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $281,569 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment
Oyster Point Pharma, Inc. · Terminated · NCT06400511 - Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5%
Glaukos Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.